Johnson & Johnson Services, Inc. and Novartis AG are Leading Players in the Pharmaceutical Drug Delivery Market

PUNE, India, 2021-Apr-13 — /EPR Network/ —

The global pharmaceutical drug delivery market is projected to reach USD 2,015.3 billion by 2025 from USD 1,430.5 billion in 2020 at a CAGR of 7.1% during the forecast period 2020-2025. Growth in this market is mainly driven by the rising prevalence of chronic diseases, growth in the biologics market, and technological advancements & new product launches.

The pharmaceutical drug delivery market is highly fragmented in nature with several big and emerging players. Johnson & Johnson, Inc. (US), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd. (Switzerland), Bayer AG (Germany), Pfizer, Inc. (US), Sanofi (France), GlaxoSmithKline plc (UK), Merck & Co., Inc. (US), 3M (US), Antares Pharma, Inc. (US), and Becton, Dickinson and Company (BD) (US) are some of the leading players operating in the global pharmaceutical drug delivery.

Players in this market pursue the strategies of product approvals, partnerships, agreements, collaborations, expansions, and acquisitions to develop and expand their market presence. Product approvals has been the key growth strategy adopted by players to expand their share in the market.

Download PDF Brochure@

Johnson & Johnson Services, Inc. is one of the leading players in the pharmaceutical drug delivery market. The leading position of Johnson & Johnson (J&J) (US) is due to its strong brand recognition. The company focuses on adopting organic as well as inorganic growth strategies to expand its presence in the drug delivery technology market. For instance, in April 2020, Janssen Pharmaceutical Companies collaborated with Emergent BioSolutions to support the manufacturing and expansion of its investigational COVID-19 vaccine. Janssen aims to supply over a billion doses of their vaccine worldwide. In January 2019, Janssen (J&J) collaborated with MeiraGTx Holdings (US) to develop, manufacture and commercialize its clinical stage inherited retinal disease drug portfolio.

Also, in 2018, the company entered into an agreement with the Oklahoma Health Care Authority (OHCA), (US). The agreement is focused on enabling the use of INVEGA SUSTENNA (paliperidone palmitate) and INVEGA TRINZA (paliperidone palmitate) in the treatment of adults with schizophrenia. Moreover, the company is focused on obtaining approvals for the timely launch of its products in the market and thereby strengthening its customer base. For instance, in 2018, the company received FDA approval for its INVOKANA (canagliflozin) to reduce the risk of major adverse cardiovascular (CV) events.

Novartis AG holds dominant position in the pharmaceutical drug delivery market. The company’s leading position can be attributed to its strong geographical presence and robust product portfolio. In order to maintain its leading position, the company significantly invests in R&D activities. In 2019, the company invested USD 9.4 billion in research and development as compared to USD 9.0 billion in 2017. This investment helped the company develop and launch new and advanced products in the drug delivery technology market. For instance, in March 2019, company received respective authority approval to market Zolgensma in Japan & US for Spinal Muscular Atrophy (SMA).

In 2018, the company received EC’s approval for the expanded indication for Kisqali (ribociclib), and also for its Xolair (omalizumab) prefilled syringe (PFS). The company also focuses on inorganic growth strategies to sustain its foothold in the market. For instance, in 2018, the company collaborated with the Harvard University (US) and the Dana-Farber Cancer Institute (US) to develop novel implantable and injectable biomaterial systems for delivering Novartis portfolio of second-generation cancer immunotherapies. Also, Novartis acquired The Medicines Company (US) in January 2020, to expand its product portfolio in CVD space by adding inclisiran (investigational cholesterol-lowering therapy).

Request Sample Pages@

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledgestore” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441

Matched content

Editor’s pick

Express Press Release Distribution